Intracerebral haemorrhage growth is associated with poor clinical outcome and is a therapeutic target for improving outcome. We aimed to determine the absolute risk and predictors of intracerebral haemorrhage growth, develop and validate prediction models, and evaluate the added value of CT angiography. In a systematic review of OVID MEDLINE-with additional hand-searching of relevant studies' bibliographies- from Jan 1, 1970, to Dec 31, 2015, we identified observational cohorts and randomised trials with repeat scanning protocols that included at least ten patients with acute intracerebral haemorrhage. We sought individual patient-level data from corresponding authors for patients aged 18 years or older with data available from brain imaging initially done 0·5-24 h and repeated fewer than 6 days after symptom onset, who had baseline intracerebral haemorrhage volume of less than 150 mL, and did not undergo acute treatment that might reduce intracerebral haemorrhage volume. We estimated the absolute risk and predictors of the primary outcome of intracerebral haemorrhage growth (defined as >6 mL increase in intracerebral haemorrhage volume on repeat imaging) using multivariable logistic regression models in development and validation cohorts in four subgroups of patients, using a hierarchical approach: patients not taking anticoagulant therapy at intracerebral haemorrhage onset (who constituted the largest subgroup), patients taking anticoagulant therapy at intracerebral haemorrhage onset, patients from cohorts that included at least some patients taking anticoagulant therapy at intracerebral haemorrhage onset, and patients for whom both information about anticoagulant therapy at intracerebral haemorrhage onset and spot sign on acute CT angiography were known. Of 4191 studies identified, 77 were eligible for inclusion. Overall, 36 (47%) cohorts provided data on 5435 eligible patients. 5076 of these patients were not taking anticoagulant therapy at symptom onset (median age 67 years, IQR 56-76), of whom 1009 (20%) had intracerebral haemorrhage growth. Multivariable models of patients with data on antiplatelet therapy use, data on anticoagulant therapy use, and assessment of CT angiography spot sign at symptom onset showed that time from symptom onset to baseline imaging (odds ratio 0·50, 95% CI 0·36-0·70; p<0·0001), intracerebral haemorrhage volume on baseline imaging (7·18, 4·46-11·60; p<0·0001), antiplatelet use (1·68, 1·06-2·66; p=0·026), and anticoagulant use (3·48, 1·96-6·16; p<0·0001) were independent predictors of intracerebral haemorrhage growth (C-index 0·78, 95% CI 0·75-0·82). Addition of CT angiography spot sign (odds ratio 4·46, 95% CI 2·95-6·75; p<0·0001) to the model increased the C-index by 0·05 (95% CI 0·03-0·07). In this large patient-level meta-analysis, models using four or five predictors had acceptable to good discrimination. These models could inform the location and frequency of observations on patients in clinical practice, explain treatment effects in prior randomised trials, and guide the design of future trials. UK Medical Research Council and British Heart Foundation.

Background: The APOE gene and its protein product is associated with a number of plasma proteins like very-low density lipoprotein (VLDL), high density lipoprotein (HDL) chylomicrons, chylomicron remnants, and plays a crucial role in lipid metabolism. The APOE gene is polymorphic and common alleles (*E2, *E3 and *E4) have been associated with a number of common and complex diseases in different populations. Due to their crucial role in metabolism and clinical significance, it is imperative that allelic variation in different populations is analysed to evaluate the usage of APOE in an evolutionary and clinical context. Aim: We report allelic variation at the APOE locus in three European and four Indian populations and evaluate global patterns of genetic variation at this locus. The large, intricate and unexpected heterogeneity of this locus in its global perspective may have insightful consequences, which we have explored in this paper. Subject and methods: Apolipoprotein E genotypes were determined in four population groups (Punjabi Sikhs, Punjabi Hindus, Maria Gonds and Koch, total individuals = 497) of India and three regionally sub-divided British populations (Nottinghamshire, East Midlands and West Midlands, total individuals = 621). The extent and distribution of APOE allele frequencies were compared with 292 populations of the world using a variety of multivariate methods. Results: Three alleles, APOE*E2, APOE*E3 and APOE*E4, were observed with contrasting variation, although *E4 was absent in the tribal population of Koch. Higher heterozygosities (>43%) in British populations reflected their greater genetic diversity at this locus. The overall pattern of allelic diversity among these populations is comparable to many European and Indian populations. At a global level, higher frequencies of the *E2 allele were observed in Africa and Oceania (0.099 ± 0.083 and 0.111 ± 0.052, respectively). Similarly, *E4 allele averages were higher in Oceania (0.221 ± 0.149) and Africa (0.209 ± 0.090), while Indian and Asian populations showed the highest frequencies of *E3 allele. The coefficient of gene differentiation was found to be highest in South America (9.6%), although the highest genetic diversity was observed in Oceania (48.7%) and Africa (46.3%). APOE*E2 revealed a statistically significant decreasing cline towards the north in Asia (r = −0.407, d.f. = 70, p < 0.05), which is not compatible with the coronary heart disease statistics in this continent. APOE*E4 showed a significant increasing cline in North European populations. Spatial autocorrelation analysis shows that the variation at this locus is influenced by ‘isolation by distance’ with a strong positive correlation for lower distances up to 1313 km. Conclusion: Overall APOE allelic variation in UK and Indian populations is comparable to previous studies but in tribal populations *E4 allele frequency was very low or absent. At a global level allelic variation shows that geography, isolation by distance, genetic drift and possibly pre-historical selection are responsible for shaping the spectrum of genetic variation at the APOE gene. Overall, APOE is a good anthropogenetic and clinical diagnostic marker. Résumé. Arrière plan: Le gène APOE et la protéine qui en dérive, est associé à de nombreuses protéines plasmatiques telles que les lipoprotéines de très basse densité (VLDL), les lipoprotéines de haute densité (HDL), chylomicrons et restants de chylomicrons et joue un rôle crucial dans le métabolisme des lipides. Le gène APOE est polymorphe et ses allèles communs (*E2, *E3 and *E4) ont été associés à de nombreuses maladies communes et complexes dans diverses populations. Du fait de leur rôle déterminant dans le métabolisme et sa signification clinique, il est impératif que la variation allélique de différentes populations soit analysée et d’évaluer l’usage de l’APOE dans les contextes clinique et évolutif. But: On présente la variation allélique du locus APOE dans trois populations européennes et quatre populations indiennes et on évalue le modèle global de variation génétique à ce locus. L’hétérogénéité forte, complexe et inattendue de ce locus dans sa perspective globale peut revêtir des significations intéressantes, qui soon explorées dans ce travail. Sujets et méthodes: Les génotypes de l’Alipoprotéine E ont été déterminés dans quatre groupes indiens (Sikhs du Panjab, Hindous du Panjab, Maria Gonds et Koch, soit au total 497 individus) et The dans trois subdivisions régionales de la population britannique (Nottinghamshire, East Midlands et West Midlands, doit au total 621 individus). L’étendue et la distribution des fréquences alléliques de APOE ont été comparées avec 292 populations dans le monde, au moyen de diverses méthodes multivariées. Résultats: Trois allèles : APOE*E2, APOE*E3 et APOE*E4, présentent des variations différentes, mais *E4 est absent de la population tribale de Koch. Les plus fortes hétérozygosités (>43%) des populations britanniques reflète leur plus grande diversité génétique à ce locus. Le schéma général de la diversité allélique de ces populations est comparable à de nombreuses populations européennes et indiennes. A un niveau global, des fréquences élevées de l’allèle *E2 ont été observées en Afrique et en Océanie (respectivement 0,099 ± 0,083 et 0,111 ± 0,052 ). De façon similaire, les niveaux de l’allèle *E4 sont plus élevés en Océanie (0,221 ± 0,149) et en Afrique (0,209 ± 0,090), alors que les populations indiennes et asiatiques présentent les plus hautes fréquences de l’allèle *E3. Le coefficient de différenciation génique le plus élevé est en Amérique du Sud (9,6%), malgré que la diversité génétique la plus grande soit observée en Océanie (48.7%) et en Afrique (46.3%). L’APOE*E2 présente un gradient décroissant statistiquement significatif (r = –0,407, d.l. = 70 p < 0,05) en direction du nord en Asie, qui n’est pas compatible avec les statistiques sur les maladies coronariennes de ce continent. APOE*E4 présente un gradient croissant significatif dans les populations nord-européennes. Une analyse d’autocorrélation spatiale montre que la variation à ce locus est influencée par l’isolement par la distance avec une corrélation fortement positive pour les distances inférieures à 1313 km. Conclusion: La variation allélique générale de l’APOE dans les populations du Royaume-Uni et les populations indiennes est comparable aux études antérieures, mais la fréquence de *E4 est très basse ou absente dans les populations tribales. A un niveau global, la variation allélique montre que la géographie, l’isolement par la distance, la dérive génétique et de possibles sélections préhistoriques, sont responsables de la forme du spectre de variation du gène APOE. Enfin, APOE est un bon marqueur anthropogénétique et de diagnostic clinique. Zusammenfassung. Hintergrund: Das APOE-Gen und sein Proteinprodukt sind mit einer Reihe von Plasmaproteinen, wie dem very-low density-Lipoprotein (VLDL), den high density-Lipoprotein (HDL)-Chylomikronen und Chylomikron-Bruchstücken vergesellschaftet, und spielen eine entscheidende Rolle im Lipidstoffwechsel. Das APOE-Gen ist polymorph, und häufige Allele (*E2, *E3 und *E4) sind in verschiedenen Populationen mit einer Reihe von häufigen und komplexen Erkrankungen in Verbindung gebracht worden. Aufgrund ihrer bedeutsamen Rolle im Stoffwechsel und ihrer klinischen Bedeutung ist es sehr wichtig, dass die allelische Variation bei verschiedenen Populationen analysiert wird, um den Verwendung von APOE in einem evolutionären und klinischen Kontext zu beurteilen. Ziel: Wir berichten über die allelische Variation auf dem APOE-Locus bei drei Europäischen und vier Indischen Populationen und untersuchen globale Muster von genetischer Variation auf diesem Locus. Die in globaler Sicht große, verwirrende und unerwartete Heterogenität dieses Locus könnte weitere Einsichten zur Folge haben, die wir in dieser Arbeit näher ausgeführt haben. Probanden und Methoden: Apolipoprotein E-Genotypen wurden bei vier Bevölkerungsgruppen bestimmt (Punjabi Sikhs, Punjabi Hindus, Maria Gonds und Koch, insgesamt 497 Personen) aus Indien und drei regional unterteilten Britischen Populationen (Nottinghamshire, East Midlands und West Midlands, insgesamt 621 Personen). Das Ausmaß und die Verteilung von APOE-Allel-Frequenzen wurden mit 292 Populationen der restlichen Welt unter Verwendung einer Vielzahl multivariater Methoden verglichen. Ergebnisses: Drei Allele, APOE*E2, APOE*E3 und APOE*E4, wurden beobachtet mit jeweils unterschiedlicher Variation, allerdings war *E4 bei der eingeborenen Koch-Population nicht vorhanden. Größere Heterozygositäten (>43%) bei den Britischen Populationen spiegelten die größere genetische Vielfalt auf diesem Locus wider. Das Gesamtmuster der allelischen Diversität bei diesen Populationen ist mit dem vieler anderer Europäischer und Indischer Populationen vergleichbar. Auf globalem Niveau beobachtet man das *E2-Allel häufiger in Afrika und Ozeanien (0,099 ± 0,083 bzw. 0,111 ± 0,052). Desgleichen war das *E4-Allel im Mittel in Ozeanien (0,221 ± 0,149) und Afrika (0,209 ± 0,090) häufiger, während Indische und Asiatische Populationen am häufigsten das *E3-Allel zeigten. Der Koeffizient der Gendifferenzierung war in Südamerika am höchsten (9,6%), wohingegen die größte genetische Diversität in Ozeanien (48,7%) und Afrika (46,3%) beobachtet wurde. APOE*E2 zeigte einen statistisch signifikanten nach Norden abnehmenden Trend in Asien (r = –0,407, d.f. = 70, p < 0,05), der nicht mit den Statistiken betreffend koronare Herzkrankheit auf diesem Kontinent übereinstimmt. APOE*E4 zeigte einen signifikanten zunehmenden Trend bei Nordeuropäischen Völkern. Eine spaziale Autokorrelationsanalyse zeigt, dass die Variation auf diesem Locus durch “Isolation aufgrund von Entfernung” (‘isolation by distance’) beeinflusst wird mit einer starken positiven Korrelation für geringere Entfernungen bis zu 1313 km. Zusammenfassung: Die gesamte allelische APOE-Variation bei Britischen und Indischen Populationen ist mit vorangegangenen Studien vergleichbar, nur bei eingeborenen Populationen tritt das *E4-Allel selten oder gar nicht auf. Global gesehen zeigt die allelische Variation, dass Geographie, Isolation aufgrund von Entfernung, Gendrift und möglicherweise prähistorische Selektion für die Ausprägung des Spektrums der genetischen Variation auf dem APOE-Gen verantwortliche sind. Insgesamt ist APOE ein guter anthropogenetischer und klinisch-diagnostischer Marker. Resumen. Antecedentes: El gen APOE y su proteína producto están asociados con una serie de proteínas plasmáticas como la lipoproteína de muy baja densidad (VLDL), la lipoproteína de alta densidad (HDL), los quilomicrones y los remanentes de quilomicrón, y juega un papel crucial en el metabolismo lipídico. El gen APOE es polimórfico y los alelos comunes (*E2, *E3 y *E4) se han asociado con una serie de enfermedades comunes y complejas en diferentes poblaciones. Debido a su papel crucial en el metabolismo y su significado clínico, es imperativo que se analice la variación alélica en diferentes poblaciones para evaluar la utilización del APOE en un contexto evolutivo y clínico. Objetivo: Se reporta la variación alélica del locus APOE en tres poblaciones europeas y cuatro hindúes y se evalúan los patrones globales de variación genética en este locus. Una amplia, intrincada e inesperada heterogeneidad en este locus en su perspectiva global podría tener reveladoras consecuencias, las cuales hemos explorado en este artículo. Sujetos y métodos: Se determinaron los genotipos de la apolipoproteína E en cuatro grupos poblacionales de la India (Punjabi Sikhs, Punjabi Hindus, Maria Gonds y Koch, con un total de 497 individuos) y tres poblaciones británicas divididas regionalmente (Nottinghamshire, East Midlands y West Midlands, con un total de 621 individuos). La magnitud y distribución de las frecuencias alélicas del APOE se compararon con 292 poblaciones de todo el mundo, utilizando diversos métodos multivariados. Resultados: Se observaron tres alelos, APOE*E2, APOE*E3 y APOE*E4, con variación contrastada, aunque el *E4 estaba ausente en la población tribal de Koch. Las elevadas heterozigosidades (>43%) en las poblaciones británicas reflejaban su mayor diversidad genética en este locus. El patrón global de diversidad alélica entre estas poblaciones es comparable al de muchas poblaciones europeas e hindúes. A nivel global, se observaron mayores frecuencias del alelo *E2 en África y Oceanía (0,099 ± 0,083 y 0,111 ± 0,052, respectivamente). De manera similar, los promedios del alelo *E4 fueron mayores en Oceanía (0,221 ± 0,149) y África (0,209 ± 0,090), mientras que las poblaciones hindúes y asiáticas mostraron mayores frecuencias del alelo *E3. Se encontró que el coeficiente de diferenciación genética era mayor en Sudamérica (9,6%), aunque la mayor diversidad genética se observó en Oceanía (48,7%) y en África (46,3%). El APOE*E2 mostró una clina decreciente hacia el norte en Asia, estadísticamente significativa (r = –0,407, g.l.= 70, p < 0,05), la cual no es compatible con las estadísticas de enfermedades coronarias en este continente. La APOE*E4 mostró una clina significativamente creciente en las poblaciones del norte de Europa. El análisis de autocorrelación espacial mostró que la variación en este locus está influenciada por el “aislamiento por distancia”, con una fuerte correlación positiva para distancias de hasta 1.313 km. Conclusión: La variación alélica global del APOE en el Reino Unido y en poblaciones de la India es comparable a las de estudios previos, aunque en las poblaciones tribales la frecuencia del alelo *E4 es muy baja o está ausente. A nivel global, la variación alélica muestra que la geografía, el aislamiento por distancia, la deriva genética y posiblemente la selección prehistórica son responsables de la conformación del espectro de la variación genética del gen APOE. En total, el APOE es un buen marcador antropogenético y de diagnóstico clínico.

Background and Purpose—: Early hematoma growth (EHG) occurs in about one third of patients with spontaneous intracerebral hemorrhage. The main aim of this study was to investigate the potential of plasma C-reactive protein (CRP) for predicting EHG after acute spontaneous intracerebral hemorrhage. Methods—: Plasma CRP was measured within 6 hours of onset (median, 120 minutes) in 399 patients with primary or vitamin K antagonist–associated spontaneous intracerebral hemorrhage and without recent infection. Computed tomography brain scans were performed at baseline and repeated within 24 hours (median, 22 hours). The primary outcome was EHG, defined as absolute growth >12.5 cm ³ or relative growth >33%. Secondary outcomes included early neurological worsening (ENW) using the Glasgow Coma Scale and 30-day mortality. Multivariable regression analyses were used to evaluate associations of CRP concentration and outcomes. Kaplan–Meier analysis was used for survival. Results—: EHG occurred in 25.8%, ENW in 19.3%, and mortality was 31.8% at 30 days. Thirty-day mortality was significantly higher in patients with ENW (hazard ratio, 3.21; 95% confidence interval, 2.00–5.17; P <0.0001) and in patients with EHG (hazard ratio, 2.13; 95% confidence interval, 1.42–3.18; P <0.0001, log-rank test). Median CRP was 12 mg/L (interquartile range, 10–17) in the EHG group and 7 mg/L (interquartile range, 4–12.1) in those without EHG ( P 10 mg/L independently predicted EHG (odds ratio, 4.71; 95% confidence interval, 2.75–8.06; P 10 mg/L is independently predictive of EHG and ENW, both of which are associated with increased mortality. Inflammation may be important in contributing to EHG and warrants further investigation.

C-reactive protein (CRP) is an important mediator and a hallmark of the acute-phase response to inflammation. High-sensitivity assays that accurately measure levels of CRP have been recommended for use in risk assessment in ischemic stroke patients. Elevation of CRP during the acute-phase response in intracerebral hemorrhage (ICH) is also associated with the outcomes such as death and vascular complications. However, no association has been found with the increased risk of ICH. The aim of this review is to synthesize the published literature on the associations of CRP with acute ICH both as a risk biomarker and predictor of short- and long-term outcomes as well as its role as a pathogenic determinant. We believe before any clinical utility, a critical appraisal of the strengths and deficiencies of the accumulated evidence is required both to evaluate the current state of knowledge and to improve the design of future clinical studies.

C-reactive protein (CRP) is a blood marker of inflammation and a hallmark of the acute-phase response. Its elevation bears negative prognostic implications for many conditions and it has also been shown to be a nonspecific predictor of long-term risk of cerebrovascular disease (CVD) in several populations, while elevations of CRP associated with the major acute-phase response following ischemic or hemorrhagic stroke are associated with death and vascular complications. High-sensitivity assays that accurately measure levels of CRP have been proposed for use in risk assessment for CVD and as a prognostic marker after an acute event, although the pathogenic and clinical significance of these associations is controversial. In this article, we critically review the literature in narrative format and describe major epidemiological studies, novel experiments and possible future developments that may inform the debate. In our discussion, we will distinguish the different pathophysiological roles of high circulating CRP concentrations in individuals with acute stroke from the modestly and persistently increased levels of CRP concentration in generally healthy subjects. However, before any clinical application is possible, a critical appraisal of the strengths and deficiencies of the accumulated evidence is required, both to consider the current state of knowledge and to inform the design of future research.

Background: Delayed cerebral ischemia (DCI) is a common and serious complication of aneurysmal subarachnoid hemorrhage (aSAH). Though many clinical trials have looked at therapies for DCI and vasospasm in aSAH, along with reducing rebleeding risks, none have led to improving outcomes in this patient population. We present an up-to-date review of the pathophysiology of DCI and its association with early brain injury (EBI). Recent Findings: Recent studies have demonstrated that EBI, as opposed to delayed brain injury, is the main contributor to downstream pathophysiological mechanisms that play a role in the development of DCI. New predictive models, including advanced monitoring and neuroimaging techniques, can help detect EBI and improve the clinical management of aSAH patients. Summary: EBI, the severity of subarachnoid hemorrhage, and physiological/imaging markers can serve as indicators for potential early therapeutics in aSAH. The microcellular milieu and hemodynamic pathomechanisms should remain a focus of researchers and clinicians. With the advancement in understanding the pathophysiology of DCI, we are hopeful that we will make strides toward better outcomes for this unique patient population.